Bringing the fundamentals into focus…
Back to Indivior Pharmaceuticals, Inc.
How Indivior Pharmaceuticals, Inc. stacks up
INDV · against 257 other Healthcare companies of similar size
Valuation
85/ 100
Near the top of its peers.
Ranked #39 of 258 · scores higher than 84% of peers
Bars: peers in each 10-point band of the valuation score30 peers with a valuation score of 80–89, including INDV · Click a bar to see the companies
Why valuation scores 85?
Weighted metrics compared with all Healthcare companies.Mainly thanks to its earnings yield and EBITDA yield, which are stronger than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -2.6% vs peer median 0.0%
- more operating profit (EBITDA) for the company's total value: stronger than 86% of peers. EBITDA yield: 9.5% vs peer median 4.0%
- higher earnings for the price paid: stronger than 90% of peers. Earnings yield: 8.3% vs peer median 1.5%
Metric by metric
Position: dot = INDV, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | INDV | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 253 reported | 7.7% | 2.5% | 89% | 30% | |
| EBITDA yieldHigher is better · 253 reported | 12.6% | 4.8% | 90% | 50% | |
| Free cash flow yieldHigher is better · 138 reported | -2.6% | 0.9% | 34% | 20% | |
| Book yieldHigher is better · 253 reported | -4.9% | 27.3% | 1% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around INDVScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score